Restaging Transurethral Resection of Bladder Tumours after BCG Immunotherapy Induction in Patients with T1 Non-Muscle-Invasive Bladder Cancer Might not Be Associated with Oncologic Benefit

Background and Purpose: The European Association of Urology guidelines recommend restaging transurethral resection of bladder tumours (reTURB) 2–6 weeks after primary TURB. However, in clinical practice some patients undergo a second TURB procedure after Bacillus Calmette-Guérin immunotherapy (BCG)i...

Descripción completa

Detalles Bibliográficos
Autores principales: Krajewski, Wojciech, Moschini, Marco, Nowak, Łukasz, Poletajew, Sławomir, Tukiendorf, Andrzej, Afferi, Luca, Teoh, Jeremy, Muilwijk, Tim, Joniau, Steven, Tafuri, Alessandro, Antonelli, Alessandro, Gozzo, Alessandra, Mari, Andrea, Di Trapani, Ettore, Hendricksen, Kees, Alvarez-Maestro, Mario, Serrano, Andrea Rodriguez, Simone, Giuseppe, Zamboni, Stefania, Simeone, Claudio, Marconi, Maria Cristina, Mastroianni, Riccardo, Ploussard, Guillaume, Rajwa, Paweł, Laukhtina, Ekaterina, Zdrojowy-Wełna, Aleksandra, Kołodziej, Anna, Paradysz, Andrzej, Tully, Karl, Krajewska, Joanna, Piszczek, Radosław, Xylinas, Evanguelos, Zdrojowy, Romuald
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7602446/
https://www.ncbi.nlm.nih.gov/pubmed/33076249
http://dx.doi.org/10.3390/jcm9103306

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7602446/
https://www.ncbi.nlm.nih.gov/pubmed/33076249
http://dx.doi.org/10.3390/jcm9103306

Ejemplares similares